Gary K. Lee - 11 Feb 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Mark Meltz, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
11 Feb 2026
Net transactions value
-$39,085
Form type
4
Filing time
12 Feb 2026, 20:44:57 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Gary K. Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Mark Meltz, Attorney-in-Fact 12 Feb 2026 0001907345

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale $39,085 -1,671 -9% $23.39 16,938 11 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.
F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.6305 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.